News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Adlyfe Appoints Roxanne Duan as Vice President of Research



9/17/2007 9:40:21 AM

ROCKVILLE, Md., Sept. 17 /PRNewswire/ -- Adlyfe, a private company developing novel diagnostic testing technologies for early targets of amyloid diseases, announced today that it has appointed Roxanne Duan, Ph.D. as Vice President of Research. Dr. Duan will be responsible for overseeing the Adlyfe's Research efforts and will report directly to the Chief Executive Officer.

Duan comes to Adlyfe with nearly two decades of experience. Most recently, Dr. Duan served as Vice President of Research at Functional Genetics, Inc., where she made major impact on developing antibody therapeutics for infectious diseases and improving a gene perturbation technology that facilitated drug target discovery and validation. Prior to Functional Genetics, Dr. Duan was the project leader and co-inventor of several clinical protein therapeutic candidates at Human Genome Sciences (HGS), covering areas of cardiovascular diseases, wound repair, and diabetes. In addition, she holds more than 20 issued patents in the area of protein therapeutics and more than 25 peer reviewed publications.

Dr. Duan began her career as a Senior Research Fellow at the National Cancer Institute where she studied tumor suppressor genes. She received her B.Sc. in Pharmacy from National Taiwan University and her Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco and worked as a postdoctoral fellow at the Howard Hughes Medical Research Institute at the University of California, San Francisco, on growth factors and their application in cardiovascular diseases.

Alan Rudolph, President and CEO of Adlyfe, said, "We are delighted that Roxanne has joined Adlyfe in this important new role. Her experience brings a critical skill set to our rapidly growing diagnostic product development activities. Her experience in protein biochemistry and development of protein based assays be instrumental to our efforts to develop diagnostic assays for neurodegenerative diseases such as Alzheimer's disease. As the Company enters its next phase of growth, we are excited to have her on board to support our efforts to develop this novel technology and deliver it to the marketplace."

Roxanne Duan commented, "I am excited to become a part of Adlyfe and to join its excellent research team. I look forward to contributing to the development of this truly novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain diseases."

About Adlyfe

Adlyfe Inc. was established early in 2003 to develop novel technologies for blood testing for early targets of amyloid diseases. Adlyfe is developing a novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain and amyloid diseases such as Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jacob disease, Huntington's disease, systemic amyloidosis, diabetes and other diseases.

The Company's novel technology is based on the synthesis of small peptide, or Pronucleon (TM) ligands, that are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes (structural changes in shape) associated with amyloid aggregation (and eventual amyloid plaque formation). These aggregates are associated with disease state progression in a number of brain-wasting and amyloid diseases.

Adlyfe, a privately-held corporation, was initially funded by the Defense Advanced Research Projects Agency (DARPA), the U.S. Army Medical Research and Materiel Command, the National Heart, Lung and Blood Institute, and Britain's Department for Environment, Food and Rural Affairs. More recently, Adlyfe raised additional funding with venture capital firms Canaan Venture Partners and Burrill Associates.

Internet Website: www.adlyfe.com Media: Janine McCargo 1-646-536-7033 jmccargo@theruthgroup.com

Adlyfe

CONTACT: Media: Janine McCargo, of The Ruth Group for Adlyfe,+1-646-536-7033, jmccargo@theruthgroup.com


Read at BioSpace.com


comments powered by Disqus
Adlyfe
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES